Pediatric versus Adult High Grade Glioma: Immunotherapeutic and Genomic Considerations

Authors

Payal Aggarwal, Department of Pediatrics, New York Medical College, Valhalla, NY, United States.
Wen Luo, Department of Pediatrics, New York Medical College, Valhalla, NY, United States.Follow
Katherine C. Pehlivan, Department of Pediatrics, New York Medical College, Valhalla, NY, United States.Follow
Hai Hoang, Department of Pediatrics, New York Medical College, Valhalla, NY, United States.
Prajwal Rajappa, Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
Timothy P. Cripe, Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
Kevin A. Cassady, Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.
Dean A. Lee, Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.Follow
Mitchell S. Cairo, Department of Pediatrics, New York Medical College, Valhalla, NY, United States.Follow

Author Type(s)

Faculty, Resident/Fellow

DOI

10.3389/fimmu.2022.1038096

Journal Title

Frontiers in Immunology

First Page

1038096

Document Type

Article

Publication Date

1-1-2022

Department

Pediatrics

Abstract

High grade gliomas are identified as malignant central nervous tumors that spread rapidly and have a universally poor prognosis. Historically high grade gliomas in the pediatric population have been treated similarly to adult high grade gliomas. For the first time, the most recent classification of central nervous system tumors by World Health Organization has divided adult from pediatric type diffuse high grade gliomas, underscoring the biologic differences between these tumors in different age groups. The objective of our review is to compare high grade gliomas in the adult versus pediatric patient populations, highlighting similarities and differences in epidemiology, etiology, pathogenesis and therapeutic approaches. High grade gliomas in adults versus children have varying clinical presentations, molecular biology background, and response to chemotherapy, as well as unique molecular targets. However, increasing evidence show that they both respond to recently developed immunotherapies. This review summarizes the distinctions and commonalities between the two in disease pathogenesis and response to therapeutic interventions with a focus on immunotherapy.

Recommended Citation

Aggarwal, P., Luo, W., Pehlivan, K. C., Hoang, H., Rajappa, P., Cripe, T. P., Cassady, K. A., Lee, D. A., & Cairo, M. S. (2022). Pediatric versus Adult High Grade Glioma: Immunotherapeutic and Genomic Considerations. Frontiers in Immunology, 13, 1038096. https://doi.org/10.3389/fimmu.2022.1038096